GlassScriptPhysician profile
Harold R Huff
NPI 1720194947
$5,232.45
in general payments reported to CMS, 2019-2025
44 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $229 · 2021: $548 · 2022: $844 · 2023: $1,007 · 2024: $1,137 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $433.90 | 2019-2025 | Breztri, Airsupra, Bydureon |
| Novo Nordisk INC | $344.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $335.39 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.35 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $321.44 | 2019-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.45 | 2019-2025 | Xifaxan |
| Pfizer INC. | $220.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $215.73 | 2022-2025 | |
| Abbott Laboratories | $195.35 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $162.24 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $94.33 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $92.16 | 2022-2024 | |
| Antares Pharma, INC. | $84.38 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Boston Scientific Corporation | $83.96 | 2021-2023 | Watchman Access System |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $74.08 | 2019-2020 | |
| Medtronic, INC. | $71.66 | 2022-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $67.14 | 2021-2025 | Vaxneuvance, Rotateq, Capvaxive |
| Astellas Pharma US INC | $64.17 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $53.10 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $50.83 | 2021-2022 | |
| Genentech USA, INC. | $45.04 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $40.71 | 2024-2025 | Gemtesa |
| Neos Therapeutics, LP | $40.43 | 2020-2022 | |
| Allergan, INC. | $38.25 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.86 | 2019-2021 | |
| Exact Sciences Corporation | $33.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $33.21 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $27.88 | 2023-2024 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $25.55 | 2019-2022 | |
| Madrigal Pharmaceuticals | $22.97 | 2024 | Resmetirom |
| Philips North America LLC | $22.86 | 2019 | |
| Pulmonx Corporation | $22.84 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Biogen, INC. | $22.34 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $22.01 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.97 | 2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $18.43 | 2025 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $16.80 | 2022 | |
| Halozyme INC | $16.72 | 2023 | |
| Dexcom, INC. | $15.92 | 2020 | |
| Daiichi Sankyo INC. | $14.32 | 2023 | Injectafer |
| Corcept Therapeutics | $13.55 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.